National Resilience Inc. (Resilience), a technology-focused biomanufacturing company dedicated to broadening access to complex medicines, has expanded its clinical and commercial drug product manufacturing capabilities with the goal of providing over 200 million units to its partners across its manufacturing network by 2025 in support of multiple modalities and therapeutic indications, including GLP-1.   This expansion aims to address the biomanufacturing industry’s growing demands within the ...